Background: Herbomineral formulations are being successfully used in Ayurvedic therapeutics since centuries. Though the preclinical safety of these formulations is established, there have been reports questioning the safety of their metallic contents, especially the presence of heavy metals. As such, it becomes imperative for the contemporary practitioners of Ayurveda to document and publish their observations on the safety of classical herbomineral formulations; as such studies will enable the scientific community to believe traditional systems too as evidence based on account of safety and efficacy.
Aim: The current work was an observational study in effort to document the safety of Chandraprabha Vati with objective
to review and report dose related adverse effects and its safety.
Method: The study data was collected from the hospital software records to survey the prescription patterns in the regular OPD and also to report any untoward affects of Chandraprabha Vati. The dose related adverse effects / safety of Chandraprabha Vati were reviewed and the observations were reported.
Results & Conclusion: There were no serious adverse reactions or toxicity symptoms with Chandraprabha Vati administered orally at doses of 500-1000 mg/ day given over 1 - 4 months.
Conclusion: Chandraprabha Vati, an Ayurvedic metallo-herbo- mineral formulation is safe when administered in prescribed doses.
Chandraprabha Vati, Heavy metal, Herbomineral, Safety
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A,
United European gastroenterology journal. 2021; 9(1): 102-109
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Kappos L, Cohan S, Arnold DL, Robinson RR, Holman J, Fam S, Parks B, Xiao S, Castro-Borrero W
Therapeutic advances in neurological disorders. 2021; 14(): 1756286420987941
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.
Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P
Clinical obesity. 2021; 11(2): e12432
Effect of microcystins at different rice growth stages on its yield, quality, and safety.
Liang C, Ma X, Liu H
Environmental science and pollution research international. 2021; 28(11): 13942-13954
Genotoxicity Study of (Spreng.) Moldenke.
Ribeiro RCL, Botelho ELL, Donadel G, Ames ML, Nunes B, Tramontini S, Soares AA, Alberton O, Jacomassi E, Gasparotto Junior A
Journal of medicinal food. 2021; ():
Effectiveness and safety review of Chinese herbal sachets for external use in the treatment of COVID-19 pandemic: A protocol for systematic review and meta-analysis.
Ju J, Yan C, Wang H, Ding Y, Zhang Y, Jia H
Medicine. 2021; 100(12): e25156
The bio-availability and accumulation of the trace elements in rock-soil-fruit system in carbonatite regions of different stratums: Critical soil factors and transfer models.
Lei M, Wang Y, Guo G, Zhang D, Zhao X
The Science of the total environment. 2021; 760(): 143328
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma.
Kyriakou S, Cheung W, Mantso T, Mitsiogianni M, Anestopoulos I, Veuger S, Trafalis DT, Franco R, Pappa A, Tetard D, Panayiotidis MI
Investigational new drugs. 2021; ():